Athenex announced the exit of its 503B sterile compounding business. 503B product sales accounted for approximately 19% of Athenex’s total product sales in the third quarter of 2022. The Company will continue to focus on creating value by advancing its cell therapy pipeline as well as monetizing non-core assets.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ATNX:
- Athenex Exits 503B Sterile Compounding Business
- Athenex Announces Positive Results of Special Stockholder Meeting
- Athenex Announces Closing of the Sale of its China API Business
- Athenex Announces Receipt of Positive Nasdaq Listing Determination
- Athenex Provides Third Quarter 2022 Financial Results and Business Update